ACHL: AI 评分 47/100 — AI 分析 (4月 2026)

Achilles Therapeutics plc is a clinical-stage immuno-oncology company focused on developing precision T cell therapies for solid tumors. Their personalized approach targets clonal neoantigens to provide individualized cancer treatments.

Key Facts: AI Score: 47/100 Sector: Healthcare

公司概况

概要：

Achilles Therapeutics plc, a clinical-stage immuno-oncology company, pioneers precision T-cell therapies targeting clonal neoantigens in solid tumors. Their personalized approach, focusing on individualized cancer treatments, positions them within the competitive biotechnology landscape, addressing unmet needs in advanced non-small cell lung cancer and metastatic melanoma.

ACHL是做什么的？

Achilles Therapeutics plc, founded in 2016 and headquartered in London, is a clinical-stage immuno-oncology biopharmaceutical company focused on developing precision T cell therapies for the treatment of solid tumors. The company's approach centers on targeting clonal neoantigens, unique markers present on cancer cells, to create personalized immunotherapies. Their lead product candidates include CHIRON, currently in Phase I/IIa clinical trials for advanced non-small cell lung cancer (NSCLC), and THETIS, also in Phase I/IIa trials for metastatic or recurrent melanoma. These trials aim to assess the safety and efficacy of Achilles' personalized T cell therapies in patients with advanced cancers. Beyond NSCLC and melanoma, Achilles is also developing products targeting other solid tumors, including head and neck squamous cell carcinoma, renal cell carcinoma, triple-negative breast cancer, and bladder cancer. The company's evolution from Achilles TX Limited to Achilles Therapeutics Plc in February 2021 reflects its commitment to advancing its pipeline of personalized cancer immunotherapies. Achilles Therapeutics operates with 204 employees, focusing on research, development, and clinical trials to bring innovative treatments to patients with significant unmet medical needs.

ACHL的投资论点是什么？

Achilles Therapeutics presents a high-risk, high-reward investment opportunity within the immuno-oncology space. The company's focus on personalized T-cell therapies targeting clonal neoantigens offers a novel approach to treating solid tumors. Key value drivers include positive clinical trial data from the CHIRON and THETIS trials, which could lead to accelerated regulatory pathways. Growth catalysts include expansion into additional solid tumor indications and potential partnerships with larger pharmaceutical companies. However, the company faces significant risks, including clinical trial failures, regulatory hurdles, and competition from established players in the immunotherapy market. With a market cap of $0.06 billion and a negative P/E ratio of -0.85, Achilles Therapeutics' valuation is highly dependent on successful clinical development and future commercialization of its therapies.

ACHL在哪个行业运营？

Achilles Therapeutics operates within the rapidly evolving immuno-oncology market, which is projected to reach $79.4 billion by 2028. The industry is characterized by intense competition, with numerous companies developing novel immunotherapies, including checkpoint inhibitors, CAR-T cell therapies, and cancer vaccines. Achilles' focus on personalized T-cell therapies targeting clonal neoantigens differentiates it from competitors, offering the potential for more precise and effective cancer treatments. The company's success depends on its ability to navigate the complex regulatory landscape, secure funding, and demonstrate clinical efficacy in its ongoing trials.

Biotechnology

Healthcare

ACHL有哪些增长机遇？

Expansion into Additional Solid Tumor Indications: Achilles Therapeutics has the opportunity to expand its personalized T-cell therapy platform into additional solid tumor indications beyond NSCLC and melanoma, such as head and neck squamous cell carcinoma, renal cell carcinoma, triple-negative breast cancer, and bladder cancer. Each of these indications represents a significant market opportunity, with a combined market size estimated at billions of dollars. Success in these areas would significantly increase the company's revenue potential and market share. This expansion is expected to occur over the next 3-5 years, contingent on positive clinical trial data.
Strategic Partnerships with Larger Pharmaceutical Companies: Achilles Therapeutics could pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its therapies. These partnerships could provide access to additional funding, expertise, and resources, as well as a broader distribution network. The potential for such partnerships is high, given the increasing interest in personalized cancer immunotherapies. These partnerships could materialize within the next 2-3 years, depending on clinical trial progress and market demand.
Advancements in Manufacturing and Scalability: Improving the manufacturing process and scalability of its personalized T-cell therapies is crucial for Achilles Therapeutics to meet future demand and reduce costs. Investing in advanced manufacturing technologies and streamlining the production process could significantly improve the company's profitability and competitiveness. This is an ongoing process, with continuous improvements expected over the next several years.
Securing Regulatory Approvals and Market Access: Obtaining regulatory approvals from the FDA and other regulatory agencies is essential for Achilles Therapeutics to commercialize its therapies and generate revenue. Successfully navigating the regulatory landscape and securing market access in key markets, such as the United States and Europe, will be critical for the company's long-term success. Regulatory decisions are expected within the next 2-4 years, following the completion of clinical trials.
Development of Next-Generation T-Cell Therapies: Achilles Therapeutics can invest in the development of next-generation T-cell therapies with enhanced efficacy and safety profiles. This could involve incorporating new technologies, such as gene editing or novel targeting strategies, to improve the performance of its therapies. This research and development effort is expected to yield results over the next 5-7 years, leading to the development of more advanced and effective cancer treatments.

Achilles Therapeutics is currently running Phase I/IIa clinical trials for CHIRON in advanced non-small cell lung cancer.
Achilles Therapeutics is currently running Phase I/IIa clinical trials for THETIS in metastatic or recurrent melanoma.
The company was founded in 2016, indicating it is still in the early stages of its development.
Achilles Therapeutics changed its name from Achilles TX Limited in February 2021.
The company has 204 employees, reflecting its scale as a clinical-stage biopharmaceutical company.

ACHL提供哪些产品和服务？

Develops personalized T cell therapies for solid tumors.
Targets clonal neoantigens, unique markers on cancer cells.
Conducts Phase I/IIa clinical trials for advanced non-small cell lung cancer (NSCLC).
Conducts Phase I/IIa clinical trials for metastatic or recurrent melanoma.
Develops products for head and neck squamous cell carcinoma.
Develops products for renal cell carcinoma.
Develops products for triple-negative breast cancer.
Develops products for bladder cancer.

ACHL如何赚钱？

Develops precision T cell therapies in-house.
Outlicenses or partners with larger pharmaceutical companies for commercialization.
Generates revenue through milestone payments and royalties on sales of approved therapies.

Patients with advanced solid tumors, including NSCLC and melanoma.
Oncologists and other healthcare professionals who treat cancer patients.
Hospitals and cancer centers that administer T cell therapies.

Proprietary technology for identifying and targeting clonal neoantigens.
Personalized approach to T cell therapy development.
Strong intellectual property portfolio protecting its technology and products.

什么因素可能推动ACHL股价上涨？

Upcoming: Interim data readout from the CHIRON Phase I/IIa clinical trial for advanced NSCLC (H2 2026).
Upcoming: Interim data readout from the THETIS Phase I/IIa clinical trial for metastatic or recurrent melanoma (H2 2026).
Ongoing: Enrollment and patient recruitment in ongoing clinical trials.
Potential: Announcement of strategic partnerships or collaborations with larger pharmaceutical companies (2026-2027).

ACHL的主要风险是什么？

Potential: Clinical trial failures or delays.
Potential: Regulatory hurdles and delays in obtaining approvals.
Ongoing: Competition from established players in the immunotherapy market.
Ongoing: High cash burn rate and the need for additional financing.
Potential: Negative impact from economic downturn and reduced healthcare spending.

ACHL的核心优势是什么？

Proprietary technology for targeting clonal neoantigens.
Personalized approach to T cell therapy development.
Strong intellectual property portfolio.
Experienced management team.

ACHL的劣势是什么？

Clinical-stage company with no approved products.
High cash burn rate.
Reliance on successful clinical trial outcomes.
Limited manufacturing capacity.

ACHL有哪些机遇？

Expansion into additional solid tumor indications.
Strategic partnerships with larger pharmaceutical companies.
Advancements in manufacturing and scalability.
Securing regulatory approvals and market access.

ACHL面临哪些威胁？

Clinical trial failures.
Regulatory hurdles.
Competition from established players in the immunotherapy market.
Economic downturn and reduced healthcare spending.

ACHL的竞争对手是谁？

AlloVir, Inc. — Focuses on allogeneic T cell therapies for viral diseases. — (ALVR)
Heat Biologics, Inc. — Developing cell-based therapies for cancer. — (HTBX)
Kronos Bio, Inc. — Focuses on developing therapies that target dysregulated transcription factors. — (KRON)
Quince Therapeutics, Inc. — Develops therapeutics for debilitating diseases. — (QNCX)
Rani Therapeutics Holdings, Inc. — Develops a robotic pill to deliver biologics orally. — (RNTX)

Key Metrics

MoonshotScore: 47/100

Company Profile

CEO: Iraj Ali
Headquarters: London, GB
Employees: 204
Founded: 2021

AI Insight

AI analysis pending for ACHL

ADR Level: 2
ADR Ratio: 1:1

常见问题

What does Achilles Therapeutics plc do?

Achilles Therapeutics plc is a clinical-stage immuno-oncology company focused on developing personalized T cell therapies for solid tumors. The company's approach centers on targeting clonal neoantigens, unique markers present on cancer cells, to create individualized immunotherapies. Their lead product candidates, CHIRON and THETIS, are currently in Phase I/IIa clinical trials for advanced non-small cell lung cancer and metastatic melanoma, respectively. Achilles aims to provide more precise and effective cancer treatments by leveraging the patient's own immune system to target and destroy cancer cells.

What do analysts say about ACHL stock?

Analyst coverage of Achilles Therapeutics is limited, reflecting its status as a clinical-stage company. Current analyst consensus is Unknown, with valuations highly dependent on clinical trial outcomes and future commercialization potential. Key valuation metrics include potential peak sales of its lead product candidates and the probability of regulatory approval. Growth considerations include expansion into additional solid tumor indications and potential partnerships. Investors should conduct their own due diligence and consider the inherent risks associated with investing in early-stage biotechnology companies.

What are the main risks for ACHL?

Achilles Therapeutics faces several key risks, including the potential for clinical trial failures or delays, which could significantly impact its valuation and future prospects. Regulatory hurdles and delays in obtaining approvals from the FDA and other regulatory agencies also pose a significant risk. The company operates in a highly competitive market, facing competition from established players in the immunotherapy space. Additionally, Achilles has a high cash burn rate and will likely require additional financing in the future, which could dilute existing shareholders. Economic downturns and reduced healthcare spending could also negatively impact the company's performance.